Skip to main content

STORIES

Children’s Mercy Receives Renewed NIH Funding to Continue Collaborative Pediatric Pharmacology Fellowship Program

STORIES

Children’s Mercy Receives Renewed NIH Funding to Continue Collaborative Pediatric Pharmacology Fellowship Program

Headshot of Jennifer L. Goldman, MD
Jennifer L. Goldman, MD
Director, Antimicrobial Stewardship & Drug Safety Service; Associate Professor of Pediatrics, University of Missouri-Kansas City School of Medicine; Research Assistant Professor of Pediatrics, University of Kansas School of Medicine
Full Biography
Headshot of Jonathan B. Wagner, DO
Jonathan B. Wagner, DO
Division Director, Clinical Pharmacology, Toxicology & Therapeutic Innovation; Associate Professor of Pediatrics, University of Missouri-Kansas City School of Medicine
Full Biography

Children’s Mercy and the Division of Clinical Pharmacology was recently notified that their Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (T32) from the National Institutes of Health was renewed for another cycle. The $1,259,655 in funding will cover an additional five years and comes from NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Jennifer Goldman, MD, (Program Director) and Jonathan Wagner, DO, (Associate Program Director) serve as co-Principal Investigators on the project titled “Children’s Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology”. The funding will allow the Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation at Children’s Mercy to continue offering one of the largest, most diverse, Pediatric Clinical Pharmacology post-doctoral training programs in the U.S.

The program is constituted by 17 faculty members across the institution, including clinicians cross-trained in a wide variety of hospital specialties along with basic/translational scientists, all of whom have made substantial contributions in the areas of pharmacogenetics, pharmacometrics, and early phase clinical trial design. It combines robust didactic and experiential training in pharmacogenetics/genomics, metabolomics, pharmacometrics, pharmacoepidemiology, drug development, and the responsible conduct of research. It also offers unique elective opportunities.

Trainees affiliate with the program for a minimum of two years. Under the direction of a junior mentor, a senior mentor, and a scholarship oversight committee, fellows complete both a clinical and translational research, produce publications/presentations, and submit applications for competitive peer-reviewed funding as they develop a plan to transition to independence.

Since its inception, the training program at CM has trained 24 pediatric clinical pharmacology fellows who during their fellowship period have collectively delivered 118 scientific presentations, prepared 102 peer-reviewed manuscripts and successfully competed for over $1,500,000 in intramural and extramural funding. The program is one of only three American Board of Clinical Pharmacology accredited training programs dedicated solely to Pediatric Clinical Pharmacology and its longstanding record of excellence provides applicants with unparalleled training in the discipline.

Drs. Goldman and Wagner shared: “We are delighted to be recognized as 1 of only 4 pediatric clinical pharmacology training programs in the U.S. to be supported under this funding mechanism. It speaks to the caliber of our faculty and the quality of the trainees that graduate from our program. We couldn’t be more excited to reimagine our program and welcome new trainees over the next 5-years.”

Learn more about the Pediatric Pharmacology Fellowship Program.